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Abstract
Background: Hereditary sensory and autonomic neuropathy (HSAN) type II with WNK1/HSN2 gene mutation
is a rare disease characterized by early-onset demyelination sensory loss and skin ulceration. To the best of our
knowledge, no cases of an autonomic disorder have been reported clearly in a patient with WNK/HSN2 gene
mutation and only one case of a Japanese patient with the WNK/HSN2 gene mutation of HSAN type II was
previously reported.
Case presentation: Here we describe a 54-year-old woman who had an early childhood onset of insensitivity to
pain; superficial, vibration, and proprioception sensation disturbances; and several symptoms of autonomic failure
(e.g., orthostatic hypotension, fluctuation in body temperature, and lack of urge to defecate). Genetic analyses
revealed compound homozygous mutations in the WNK1/HSN2 gene (c.3237_3238insT; p.Asp1080fsX1). The patient
demonstrated sensory loss in the “stocking and glove distribution” but could perceive visceral pain, such as
menstrual or gastroenteritis pain. She experienced frequent fainting episodes. She had undergone exenteration of
the left metatarsal because of metatarsal osteomyelitis at 18 years. Sural nerve biopsy revealed a severe loss of
myelinated and unmyelinated nerves. She complained of severe pain in multiple joints, even on having pain
impairment. Although non-steroidal anti-inflammatory drugs are generally more effective than acetaminophen
for arthritis, in our case, they were ineffective and acetaminophen (2400 mg/day) adequately controlled her pain
and improved quality of life. Over 3 months, the numerical rating scale, pain interference scale of the Brief Pain
Inventory, and the Pain Catastrophizing Scale decreased from 6/10 to 3/10, from 52/70 to 20/70, and from 22/52 to
3/52 points, respectively.
Conclusions: This is the second reported case of a Japanese patient with WNK/HSN2 gene mutation of HSAN type II
and the first reported case of an autonomic disorder in a patient with the WNK/HSN2 gene mutation. Acetaminophen
adequately controlled arthropathy related pain in a patient with congenital impairment of pain sensation.
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Background
Hereditary sensory and autonomic neuropathies (HSANs)
are clinical and genetic disorders of the peripheral nerve
[1]. HSANs are linked to 12 genes and have been classified
into types I–V on the basis of age at onset, mode of inher-
itance, and predominant clinical symptoms [1]. Patients
with HSAN type II present with loss of pain, temperature,
and touch and mutations in the hands and feet [1]. Auto-
nomic disorder is not a dominant feature of HSAN type
II, although this disease is called “hereditary sensory and
autonomic neuropathy” [1]. HSAN type II, with mutation
in the nervous system-specific HSN2 exon of the with-
no-lysine(K)-1 (WNK1) gene (HSN2/WNK1), is a very rare
autosomal recessive disease. A few cases of WNK1/HSN2
have been reported among the following ethnic groups:
French–Canadian families (c.594delA, c.918_919insA,
c.943c > T) [2, 3], a Lebanese family (c.947delC) [4], and
two British families (c.60_61delTG + c.1168_1171delA-
CAG and c.1168_1171delACAG+ c.1168_1171delACAG)
[5] and in Austrian (c.550C > T) [6], Italian (c.255delC,
c.1089_1090insT) [6], Belgian (c.1064_1065delTC)
[6], Polish (c.539_540delAG, c.2897_2898delAG) [7],
Korean (c.1134_1135insT, c.217C > T) [8], and Japanese
(c.1134_1135insT) [9] ethnicities. With the exception of
dry hands in a Korean case, autonomic complications have
not been reported in patients with HSAN type II with
HSN/WNK1 mutation [8].
Charcot arthropathy includes deforming and de-
structive process in joints and is one of the compli-
cations of neurosensory disorders [10]. The lack of
protective sensation in patients with sensory neuropa-
thies could cause delayed identification of bone injur-
ies by overload [10]. Because of the lack of sensation
experienced by patients with Charcot arthropathy,
they are not expected to experience much pain despite
severe deformation. However, a previous study re-
ported that among 55 patients with Charcot arthropa-
thy, more than 75 % complained of pain in the foot at
the final stage of deformation, although all patients
had clinical loss of sensation [11]. The reasons for this
remain unclear.
Case presentation
A 54-year-old woman presented with loss of touch,
temperature, position, and vibration sense and taste
disorder, and she was insensitive to pain at the body
surface since infancy. She also suffered from an auto-
nomic disorder, with symptoms, such as orthostatic
hypotension, fluctuation in body temperature, and lack
of urge to defecate.
She had normal mental growth and development,
although she did not walk until 18 months of age. Her
family history was unremarkable; she had a healthy youn-
ger sister and her parents were not related (Fig. 1). She
had repeated injuries during childhood because of insensi-
tivity to pain, and she was diagnosed with Freiberg disease
at 6 years. She experienced frequent fainting episodes and
was diagnosed with an autonomic nervous system imbal-
ance at 21 years. Even in cold temperatures, she perspired
on her back and reported not needing a snowsuit. She did
not have high blood pressure.
After repeated jumping from a squatting position in
gym class at 14 years, the sole of her left foot developed
severe blisters, and the wounds transitioned into metatar-
sal osteomyelitis after a few weeks. As a result of the
refractory osteomyelitis, a left metatarsal was replaced by
an autogenous bone graft when she was 18 years. It took
approximately 10 years to recover fully from the wounds.
She had migraine since childhood until she was 20
years and took a painkiller (an antipyrine medication)
daily during that time. Although she could feel a tooth-
ache/headache, she lacked sensation on the surface of
her face, except around the jaw. She showed a “stocking
and glove distribution”, and the detection range of
sensation varied along a gradient from the periphery to
center. She could perceive visceral pain, such as menstrual
or gastroenteritis pain, which she controlled with an anti-
pyrine medication. Since 42 years of age, she started using
a cane for walking outside.
Although she had known that she was different from
others concerning pain perception since childhood, she
and her parents had never consulted a doctor regarding
the impaired pain sensation until 48 years of age.
Fig. 1 The family tree of the patient
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At 48 years of age, the patient developed sudden severe
pain and swelling in her right joint, and her previous phys-
ician diagnosed Charcot arthropathy (X-ray photograms
are shown in Fig. 2). At 50 years of age, she was confined
to a wheelchair to avoid putting weight on her joints. The
pain gradually affected multiple joints over subsequent
years. Non-steroidal anti-inflammatory drugs (NSAIDs)
improved her joint pain to a limited degree. At 54 years of
age, her joint pain became intolerable. NSAIDs were not
effective enough for her to resume activities of daily living.
Mexiletine hydrochloride treatment was not effective. She
experienced side effects of pregabalin and duloxetine. Sub-
sequently, her physician referred her to our multidisciplin-
ary center for pain management. She was diagnosed with
HSAN type II using molecular genetic analysis and was
prescribed acetaminophen (2400 mg/day), which con-
trolled her pain very well and improved her quality of life.
During our follow-up, she reported: “one day severe ‘elec-
tric-shock-like or piercing pain’ occurred, and which made
me suffer few times per hour and keeping for months after
this episode, and which was naturally decreased.”
Pain-related assessment
Brief Pain Inventory (BPI), including numerical rating scale
(NRS) [12, 13], was used to assess pain intensity and inter-
ference. Pain-related psychosocial factors were quantitated
using the Hospital Anxiety and Depression scale (HADS)
[14] and Pain Catastrophizing Scale (PCS) [15]. NRS and
pain interference scale of BPI decreased from 6/10 to 3/10
and from 52/70 to 20/70 points, respectively, over 3
months. PCS scores also decreased from 22/52 to 3/52
points. At baseline, HADS indicated normal mental state;
both the anxiety and depressive scales of HADS were rela-
tively low (both 5/21 points) despite severe pain. After 3
months, the anxiety and depressive scales of HADS de-
creased from 5/21 to 3/21 points and from 5/21 to 4/21
points, respectively.
Neurological examination
A neurological examination revealed normal mental
status, speech, and comprehension and intact cranial
nerve-innervated muscles. Manual muscle testing re-
vealed moderate weakness in the distal parts of the
extremities and mild weakness in the proximal parts.
Grip strength was significantly reduced (right, 4.0 kg;
left, 6.0 kg). Deep tendon reflexes were absent. Plantar re-
sponses were flexor on both sides. The sensory examin-
ation revealed that the tactile and pinprick sensations
were moderately decreased in the face and trunk and se-
verely diminished in the upper and lower distal extrem-
ities. Sensations were diminished in a stocking and glove
pattern. The vibration sense was reduced till the knees
and absent in the ankles. The joint position sense was
absent at the hallux. There was no apparent laterality of
the sensory disturbance. Pseudoathetosis was observed
in the upper limbs, and Romberg’s test was not positive
in the seated position. With the exception of abnormal
sweating, thermoregulatory failure, and lack of urge to
defecate, there were no signs of autonomic dysfunction,
such as pupillary responses, dry eyes, or dry mouth.
Her blood pressure was 138/85 bpm in the supine pos-
ition and 126/72 bpm while standing. The head-up tilt
test did not reveal any orthostatic intolerance. On elec-
trocardiogram, the coefficient of variation of the R-R
intervals (CVR-R) measured at rest was normal. The
early and delayed heart-to-mediastinum (H/M) ratio
was not decreased on 123I-MIBG myocardial scintigraphy
(early: 3.14, delay: 2.97).
Nerve conduction and electromyographic evaluation
The nerve conduction study revealed normal compound
muscle action potentials (CMAPs) values, except for a
slightly reduced motor nerve conduction velocity of 50.0
m/s, 41.0 m/s, and 39.0 m/s in the median, peroneal,
and tibial nerves, respectively. The velocity was in the
normal range in the ulnar nerve (>50.5 m/s) and in the
tibial and peroneal nerves (>48.0 m/s). The sensory
nerve action potentials of the median, ulnar, and sural
nerves were not evoked. The electromyography revealed
a reduction in recruitment in the distal muscles of the
upper and lower limbs. The patient was diagnosed with
pure sensory neuropathy.
Fig. 2 X-ray photograms of the legs
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Pathologic examination
Sural nerve biopsy revealed a severe loss of myelinated
and unmyelinated nerve which were observed by light
microscopy of the epon section with toluidine blue
staining (Fig. 3a, b) and electron microscopy (Fig. 4a, b).
Collagen pockets, which were indicative of unmyelinated
nerve loss, were observed by electron microscopy
(indicated by the arrows in Fig. 4c). Myelinated nerve
tissue was completely lost. The density of unmyelinated
nerve tissue (7620 per mm2), calculated by electron
microscopy, was significantly decreased. Skin biopsy was
not performed.
Molecular genetic analysis
Mutation screening was conducted as previously de-
scribed [16]. Target sequencing with 16 HSAN disease-
related genes were conducted using Illumina MiSeq
(Illumina Inc., San Diego, CA, USA). The WNK1
mutation observed in this patient was validated by Sanger
sequencing. A homozygous frame shift mutation was
identified in the WNK1/HSN2 gene c.3237_3238insT
(p.Asp1080fsX1; ENST00000537687), which was pre-
viously reported as c.1134_1135insT (p.Asp379fsX1;
ENST00000574564) [8, 9]. This mutation is absent in 1000
Genomes, ExAC, or HGVD, which comprises exome se-
quencing of 1208 Japanese individuals (http://www.geno-
me.med.kyoto-u.ac.jp/SnpDB/).
Conclusion
We would like to highlight three important points from
this case. First, this is the second case of WNK/HSN2
gene mutation of HSAN type II reported in a Japanese
patient. Second, this is the first reported case of an auto-
nomic disorder in a patient with the WNK/HSN2 gene
mutation. Third, the patient’s arthropathy-related pain,
despite congenital impairment of pain sensation, was a
noteworthy symptom.
The current patient is the second reported case of a
patient with WNK1/HSN2 gene mutation in Japan, both
of which resulted from the same homozygous mutation,
c.3237_3238insT [9]. WNK1/HSN2 with homozygous
1134–1135 ins T mutation was reported in a Japanese
patient by Takagi et al. [9], and the same mutation was
reported in Korea by Cho et al. [8].
Although an autonomic disorder has never been re-
ported in HSAN type II with the WNK1/HSN2 gene
mutation, our patient presented with several symptoms
of autonomic disturbances. In particular, the lack of urge
to defecate through decreased parasympathetic pelvic
nerve activity resulted in serious disruptions in her activ-
ities of daily living. Although there have been no reports
of hyperhidrosis in patients with HSAN type II, fluctu-
ation in body temperature is one of the most common
symptoms of autonomic failure. In the presence of par-
tial hyperhidrosis, there may be peripheral autonomic
dysfunction. WNK influences transient receptor poten-
tial vanilloid 4 (TRPV4) channel function, which con-
trols osmoregulation at the cellular level and regulates
water balance. Therefore, there is an association between
WNK1 and severe hypertension as reported previously
[17]. However, our patient did not present with hyper-
tension. Although our examination did not reveal auto-
nomic dysfunction, we think that the possibility of
autonomic failure cannot be excluded. This is the first
reported case of an autonomic disorder in a patient with
the WNK/HSN2 gene mutation, and HSAN type II
should be carefully considered because symptoms of
autonomic dysfunction appeared in our patient.
Recurrent skin ulcers on the tips of the fingers and
toes were previously reported [1, 8, 9]. Our patient had a
difficult in recovering from injury and an amputated
metatarsal due to osteomyelitis, but she did not develop
skin ulcers. Except the autonomic disorder, her neuro-
logical examination had almost the same clinical features
as those of previous patients with HSAN type II with
WNK1/HSN2 gene mutations.
NSAIDs are generally more effective than acetamino-
phen for arthritis with inflammation. However, in our
Fig. 3 Sural nerve biopsy viewed under light microscopy of the
epon section with toluidine blue staining. Light microscopy findings
(a) Low-power image, b High-power image
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patient, acetaminophen was more effective than NSAIDs
for alleviating multiple joint pain. Theoretically, her
arthropathy pain was conducted by unmyelinated nerve
fibers (C fibers) and was possibly modified by central
pain because acetaminophen was very effective for con-
trolling her pain, although she had a reduction in unmy-
elinated nerve tissue. The antinociceptive mechanism of
acetaminophen is still unclear, but the theory of multiple
pathways is supportive. Although acetaminophen in-
hibits cyclooxygenase (COX), anti-inflammatory effect of
acetaminophen is weak. Acetaminophen is lipid-soluble,
passes through the blood–brain barrier, and has an effect
on the central nerve system [18]. Acetaminophen activates
5-hydroxytryptamine 3 receptors in the serotonergic
pathways, which are part of the descending pain system,
with resulting pain relief [19]. The gamma-aminobutyric
acid receptor is associated with acetaminophen [20].
Cannabinoid is one of the key factors of acetaminophen-
induced antinociception [21]. Moreover, TRPV1 has an
important role in antinociception induced by acetamino-
phen in the brain [22].
The patient felt non-specific ‘electric shock-like or
piercing’ pain suddenly, but she was innately unable to
feel sharp pain because of complete demyelination. Her
non-specific pain might have been phantom pain, de-
rived from the central nervous system because it was
correlated with her strong emotional episode. When she
complained about non-specific pain, her father was diag-
nosed of cancer and reported a pins-and-needles sensa-
tion in his fingers due to peripheral nerve disorder,
which was caused by anti-cancer chemotherapy. He had
complained about the pins-and-needles sensation every
day, and she was told that she had empathized with and
imagined his pain. We suspect that her non-specific pain
was central pain from this emotional episode relating to
her father. A previous study reported that empathy for
pain may effectively activate pain neural circuits in an in-
dividual observing another person’s pain [23]. Consistent
with our findings, Danzier et al. reported a 32-year-old
woman with HSAN type V who experienced tension-type
headaches shortly after the sudden loss of her brother,
despite complete absence of physical pain [24].
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